Listen in as our CEO Amit Etkin and NAMI Montana executive director Matt Kuntz discuss how we are combatting trial-and-error in #psychiatry through our precision drug development approach and patient advocacy initiatives in this NBC Montana segment: https://bit.ly/3XR05e3
Alto Neuroscience’s Post
More Relevant Posts
-
𝐌𝐢𝐧𝐝𝐌𝐞𝐝'𝐬 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐀𝐧𝐱𝐢𝐞𝐭𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐌𝟏𝟐𝟎 𝐒𝐡𝐨𝐰𝐬 𝐑𝐚𝐩𝐢𝐝 𝐚𝐧𝐝 𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐞𝐝 𝐄𝐟𝐟𝐢𝐜𝐚𝐜𝐲 MindMed's MindMed MM120 demonstrated rapid, significant improvements on the Hamilton Anxiety Rating Scale (HAM-A) compared to placebo at Week 4, the trial’s primary endpoint. MM120 100 µg showed a 7.7-point improvement over placebo at Week 12, sustaining a 65% clinical response rate and 48% clinical remission rate. The FDA designated MM120 as a breakthrough therapy for Generalized Anxiety Disorder (GAD), based on Phase 2b data. MM120 was generally well-tolerated, with mild to moderate adverse events. The study isolated MM120's effects by removing additional medications and psychotherapy. Primary data analyses have been accepted for presentation at the American Psychiatric Association’s annual meeting and for publication in a leading medical journal. These results signify a significant step forward in the treatment landscape for GAD, offering hope for patients and clinicians alike. #MindMed #MM120 #AnxietyTreatment #BreakthroughTherapy #GAD #ClinicalResearch #Psychiatry #FDAApproval #MentalHealth #HealthcareInnovation
To view or add a comment, sign in
-
-
How early should we initiate long-acting injectable antipsychotics (LAIs) in the management of schizophrenia? For patients with schizophrenia, each relapse can lead to worsened symptoms, increased disability, and decreased treatment response. Tune in as Dr. Christoph Correll discusses the benefits of initiating long-acting injectable antipsychotics (LAIs) early in treatment to prevent relapses and hospitalizations. Discover insights from studies showing LAIs’ superior efficacy over oral treatments, their role in preventing emergency department visits, and strategies for proactive initiation. Enhance your practice with the latest insights on LAIs: https://ow.ly/Msbq50SFoIY #Schizophrenia #MentalHealth #LAIs #Psychiatry #EarlyIntervention
Too Soon Is Not Soon Enough: Initiation of LAIs Sooner to Manage Symptoms of Suboptimally Treated Schizophrenia
reachmd.com
To view or add a comment, sign in
-
#OpenAccess paper from the CAMH journal Differences in body mass index trajectories of adolescent psychiatric inpatients by sex, age, diagnosis and medication: an exploratory longitudinal, mixed effects analysis https://bit.ly/3vo3zFV 'Adolescents in secure psychiatric care typically report high #Obesity rates. However, longitudinal research exploring the rate and extent of change is sparse. This study aimed to analyse sex differences in longitudinal body mass index (#BMI) change for adolescents receiving treatment in a secure #Psychiatric hospital.' Authors: Justine Anthony, William Johnson, Anthony Papathomas, Kieran Breen, Florence-Emilie Kinnafick #MentalHealth #MentalHealthMatters #MentalHealthAwareness #Science #Evidence #Research #Wellbeing #Psychology #Psychiatry #Medicine
Differences in body mass index trajectories of adolescent psychiatric inpatients by sex, age, diagnosis and medication: an exploratory longitudinal, mixed effects analysis
acamh.onlinelibrary.wiley.com
To view or add a comment, sign in
-
We're thrilled to announce the publication of our study in Neuroscience and Biobehavioral Reviews (IF:8.2) , which addresses a significant gap in our understanding of the kappa opioid receptor system and its relevance to opioid use disorder (OUD)! 📢 This achievement wouldn't have been possible without the dedication of all the authors involved, and we're grateful for their contributions throughout this rewarding journey! In brief, OUD remains one of the most pressing global health challenges we've faced for years. Our research highlights the promising potential of the KOR system for advancing treatment options for OUD and developing new painkiller opioids with reduced addictive side effects. This underscores the importance of continued exploration in this field to address the complexities of addiction and pain management effectively. Check out the study if you are interested in more! https://lnkd.in/dYcajG_b #addiction #opioids #research #medicine #elsevier #psychiatry
To view or add a comment, sign in
-
-
💭 What determines medication outcomes? 👉 Did you know that things like the price of the medication and even the color of the pill can impact outcomes From placebo studies we know that red/yellow pills tend to be energizing and blue pills tend to be calming Expensive pills tend to work better, if someone knows they are on an expensive brand name medication they tend to do better than if they are on a cheap generic medication 👉 The psychological component of medication treatment in psychiatry has a profound impact on treatment outcomes. Up to half of treatment outcomes are related to placebo, this is especially true in depression treatment 🔗 Links below https://lnkd.in/eWrMTP-X. https://lnkd.in/e2Xs6Tst. #psychiatry #psychiatrist #placebo #mentalhealth #mentalhealthsupport #mentalhealthprofessionals #mentalhealthtips #mentalhealtheducation #mentalhealthmatters #medication #medicationmanagement
To view or add a comment, sign in
-
-
The problems around blinding and expectancy bias are not unique to psychedelics. Blinding success is generally low among psychiatric trials, and studies rarely report information about blinding. In fact, the proportion of antidepressant trials examining blinding success was only 7.1% between 2010 and 2020 — a slight increase from 1.79% in the previous decade (source: https://lnkd.in/ezBDZRxb). The internal validity of double-blind RCTs, the gold standard in clinical development, relies on the assumption of appropriate blinding. Blinding is particularly important in psychiatric studies because the clinical rating scales used to assess outcomes are often subjective. The widespread lack of reporting on blinding success indicates a larger problem in psychiatric research. This could be due to the many methods available for blinding assessment and questions about their trustworthiness. Formal guidelines on blinding could guide drug developers in the right direction. We’ll dive deeper into this issue in our upcoming webinar. If interested, register here: https://lnkd.in/e32JkDzs 🗓 Tuesday July 2 @ 3pm #blinding #psychiatry #psyihatrictrial #clinicaltrial #clinicaldevelopment #guideline #expectancy #bias #rct #psychedelics #fda #adcomm
To view or add a comment, sign in
-
Stopping a long-term #benzo unexpectedly raised mortality (slightly) (including overdose risk), regardless of opioid use, in new study of 353,000: https://lnkd.in/eXz7WT5g However, the lack of randomization leaves open the possibility that clinicians tend to stop #benzos in high-risk patients. I don’t think this means that staying on a benzo is good for you, but rather that withdrawal causes its own set of problems. --------------------------------------------------- Follow for research updates from the editor of the Carlat #Psychiatry Report #mentalhealth #mentalillness #anxiety (Thanks for sending the study D Calvert)
To view or add a comment, sign in
-
-
"Once I see a patient is on an antipsychotic, the first thing I want to know is when their most recent metabolic labs were done, checking their A1C, cholesterol, and when their last AIMS test was conducted.” The therapeutic value of antipsychotic drugs for individuals who need them cannot be understated. Nor can the importance of monitoring for side effects. As Jordan Howard MD, a renowned psychiatrist at CNSL, a behavioral health practice in the greater Atlanta metropolitan area (and part of Privia Health) explains, checking for metabolic side effects is an important piece of the puzzle. ⚠ But drug-induced movement disorders (DIMDs) can be overlooked. 🔍 They don’t have to be. That’s why Dr. Howard conducts regular Abnormal Involuntary Movement Scale (AIMS) assessments for his patients taking antipsychotics. 👇 Learn about the AIMS assessment and how to make it just as routine as metabolic monitoring at www.amalgamrx.com/aims #TardiveDyskinesia #TD #Psychiatry #EHRsolutions #AmalgamRx
How to make the AIMS assessment part of routine monitoring
To view or add a comment, sign in
-
There is still time to register for #NEISynapse! Attend from the comfort of your home or office via simulcast. For 3 days work with brilliant faculty and colleagues and engage in a comprehensive review of mental health treatments, side effects, drug interactions, and more. Register now! https://lnkd.in/ee9c9aRM #psychopharmacology #psychiatry #mentalhealth #cme
To view or add a comment, sign in
-
-
#OpenAccess paper from the CAMH journal Differences in body mass index trajectories of adolescent psychiatric inpatients by sex, age, diagnosis and medication: an exploratory longitudinal, mixed effects analysis https://bit.ly/3vo3zFV Adolescents in secure psychiatric care typically report high obesity rates. However, longitudinal research exploring the rate and extent of change is sparse. This study aimed to analyse sex differences in longitudinal body mass index (BMI) change for adolescents receiving treatment in a secure psychiatric hospital. Authors: Justine Anthony, William Johnson, Anthony Papathomas, Kieran Breen, Florence-Emilie Kinnafick #MentalHealth #MentalHealthMatters #MentalHealthAwareness #Science #Evidence #Research #Wellbeing #Psychology #Psychiatry #EatingDisorders
Differences in body mass index trajectories of adolescent psychiatric inpatients by sex, age, diagnosis and medication: an exploratory longitudinal, mixed effects analysis
acamh.onlinelibrary.wiley.com
To view or add a comment, sign in